v3.22.4
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Underwritten Offering
Series A  preferred stock
Common stock
Common stock
Underwritten Offering
Additional paid-in capital
Additional paid-in capital
Underwritten Offering
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Mar. 31, 2021     10,000 97,971,243          
Beginning balance at Mar. 31, 2021 $ 391,480   $ 0 $ 10   $ 590,425   $ (298) $ (198,657)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Capital contribution – stock-based compensation 41         41      
Capital contribution – expenses allocated from Roivant Sciences Ltd. 91         91      
Stock-based compensation 3,820         3,820      
Foreign currency translation adjustments 571             571  
Net loss (30,471)               (30,471)
Restricted stock units vested and settled (in shares)       6,352          
Ending balance (in shares) at Jun. 30, 2021     10,000 97,977,595          
Ending balance at Jun. 30, 2021 365,532   $ 0 $ 10   594,377   273 (229,128)
Beginning balance (in shares) at Mar. 31, 2021     10,000 97,971,243          
Beginning balance at Mar. 31, 2021 391,480   $ 0 $ 10   590,425   (298) (198,657)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Capital contribution – expenses allocated from Roivant Sciences Ltd. 100                
Net loss (109,559)                
Ending balance (in shares) at Dec. 31, 2021     10,000 115,109,833          
Ending balance at Dec. 31, 2021 505,148   $ 0 $ 12   812,933   419 (308,216)
Beginning balance (in shares) at Jun. 30, 2021     10,000 97,977,595          
Beginning balance at Jun. 30, 2021 365,532   $ 0 $ 10   594,377   273 (229,128)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Capital contribution – stock-based compensation 692         692      
Capital contribution – expenses allocated from Roivant Sciences Ltd. 38         38      
Stock-based compensation 7,669         7,669      
Foreign currency translation adjustments 169             169  
Net loss (37,703)               (37,703)
Issuance of common stock (in shares)       17,021,276          
Issuance of common stock 200,000     $ 2   199,998      
Ending balance (in shares) at Sep. 30, 2021     10,000 114,998,871          
Ending balance at Sep. 30, 2021 536,397   $ 0 $ 12   802,774   442 (266,831)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Capital contribution – stock-based compensation 205         205      
Capital contribution – expenses allocated from Roivant Sciences Ltd. 0                
Stock-based compensation 9,954         9,954      
Foreign currency translation adjustments (23)             (23)  
Net loss (41,385)               (41,385)
Restricted stock units vested and settled (in shares)       110,962          
Ending balance (in shares) at Dec. 31, 2021     10,000 115,109,833          
Ending balance at Dec. 31, 2021 505,148   $ 0 $ 12   812,933   419 (308,216)
Beginning balance (in shares) at Mar. 31, 2022     10,000 116,482,899          
Beginning balance at Mar. 31, 2022 469,825   $ 0 $ 12   824,796   404 (355,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock options exercised and restricted stock units vested and settled (in shares)       41,259          
Stock options exercised and restricted stock units vested and settled 21         21      
Capital contribution – stock-based compensation 132         132      
Stock-based compensation 7,555         7,555      
Foreign currency translation adjustments (667)             (667)  
Net loss (40,373)               (40,373)
Ending balance (in shares) at Jun. 30, 2022     10,000 116,524,158          
Ending balance at Jun. 30, 2022 436,493   $ 0 $ 12   832,504   (263) (395,760)
Beginning balance (in shares) at Mar. 31, 2022     10,000 116,482,899          
Beginning balance at Mar. 31, 2022 469,825   $ 0 $ 12   824,796   404 (355,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (151,528)                
Ending balance (in shares) at Dec. 31, 2022     10,000 129,260,254          
Ending balance at Dec. 31, 2022 414,678   $ 0 $ 13   920,197   1,383 (506,915)
Beginning balance (in shares) at Jun. 30, 2022     10,000 116,524,158          
Beginning balance at Jun. 30, 2022 436,493   $ 0 $ 12   832,504   (263) (395,760)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Capital contribution – stock-based compensation 106         106      
Stock-based compensation 8,051         8,051      
Foreign currency translation adjustments (974)             (974)  
Net loss (47,928)               (47,928)
Restricted stock units vested and settled (in shares)       89,930          
Ending balance (in shares) at Sep. 30, 2022     10,000 116,614,088          
Ending balance at Sep. 30, 2022 395,748   $ 0 $ 12   840,661   (1,237) (443,688)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock options exercised and restricted stock units vested and settled (in shares)       146,166          
Stock options exercised and restricted stock units vested and settled 403         403      
Capital contribution – stock-based compensation 50         50      
Stock-based compensation 8,856         8,856      
Foreign currency translation adjustments 2,620             2,620  
Net loss (63,227)               (63,227)
Issuance of common stock (in shares)         12,500,000        
Issuance of common stock   $ 70,228     $ 1   $ 70,227    
Ending balance (in shares) at Dec. 31, 2022     10,000 129,260,254          
Ending balance at Dec. 31, 2022 $ 414,678   $ 0 $ 13   $ 920,197   $ 1,383 $ (506,915)